Everything below concerns MC4R. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Some glycerol-based ear medications for use in removing excess wax as well as relieving ear conditions such as otitis media and swimmer's ear. Some previous diet products such as Ayds. Some condoms designed to prevent premature ejaculation. Benzocaine largely inhibits sensitivity on the penis, and can allow for an erection to be maintained longer (in a continuous act) by delaying ejaculation. Conversely, an erection will also fade faster if stimulus is interrupted. Benzocaine mucoadhesive patches have been used in reducing orthodontic pain. In Poland it is included, together with menthol and zinc oxide, in the liquid powder (not to be confused with the liquid face powder) used mainly after mosquito bites. Today's ready-made Pudroderm was once used there as pharmaceutical compound.
=== 1953 === January 20: Dwight D. Eisenhower becomes President, with John Foster Dulles as Secretary of State. February 3: The Batepá massacre occurred in São Tomé and Príncipe. February 28: Balkan Pact is signed by Yugoslavia, Greece and Turkey. The pact's main objective is to deter Soviet expansionism. March 5: Stalin dies, setting off a power struggle to succeed him. NATO debates possibility of a fresh start. May 31–June 2: The 1953 Plzeň uprising was violently suppressed by the Czechoslovak government. June 2: Elizabeth II is crowned Queen of the United Kingdom and the other Commonwealth realms, at Westminster Abbey. June 17: Uprising of 1953 in East Germany crushed by Soviet troops. July 26: The Cuban Revolution begins as the 26th of July Movement led by Fidel Castro attempts to overthrow the government of Fulgencio Batista. July 27: An armistice agreement ends fighting in the Korean War, after Eisenhower threatens the use of nuclear weapons. August 19: The Central Intelligence Agency (CIA) and the British MI6 assists a royalist coup that restores Mohammad Reza Pahlavi to power as the Shah of Iran and ousts Prime Minister Mohammed Mosaddeq (Operation Ajax). The coup was organized because of Iranian nationalization of the oil industry and fears of Iran joining the Soviet camp. September 7: Nikita Khrushchev becomes leader of the Communist Party of the Soviet Union. His main rival, Lavrentiy Beria, is executed in December. September 23: The Pact of Madrid is signed by Spain and the United States.
Rotary evaporation for high boiling hydrogen bond-forming solvents such as water is often a last recourse, as other evaporation methods or freeze-drying (lyophilization) are available. This is partly due to the fact that in such solvents, the tendency to "bump" is accentuated. The modern centrifugal evaporation technologies are particularly useful when one has many samples to do in parallel, as in medium- to high-throughput synthesis now expanding in industry and academia. Evaporation under vacuum can also, in principle, be performed using standard organic distillation glassware — i.e., without rotation of the sample. The key advantages in use of a rotary evaporator are
==== Hypoglycemic unawareness ==== Recurrent episodes of hypoglycemia can lead to hypoglycemic unawareness, or the decreased ability to recognize hypoglycemia. As diabetics experience more episodes of hypoglycemia, the blood glucose level which triggers symptoms of hypoglycemia decreases. In other words, people without hypoglycemic unawareness experience symptoms of hypoglycemia at a blood glucose of about 55 mg/dL (3.0 mmol/L). Those with hypoglycemic unawareness experience the symptoms of hypoglycemia at far lower levels of blood glucose. This is dangerous for a number of reasons. The hypoglycemic person not only gains awareness of hypoglycemia at very low blood glucose levels, but they also require high levels of carbohydrates or glucagon to recover their blood glucose to normal levels. These individuals are also at far greater risk of severe hypoglycemia. While the exact cause of hypoglycemic unawareness is still under research, it is thought that these individuals progressively begin to develop fewer adrenergic-type symptoms, resulting in the loss of neuroglycopenic-type symptoms. Neuroglycopenic symptoms are caused by low glucose in the brain, and can result in tiredness, confusion, difficulty with speech, seizures, and loss of consciousness. Adrenergic symptoms are caused by the body's reaction to low glucose in the brain, and can result in fast heart rate, sweating, nervousness, and hunger. See section above on Signs and Symptoms for further explanation of neuroglycopenic symptoms and adrenergic symptoms.
==== Eye Caps ==== Eye caps are used when setting the facial features to close the eyes. They are plastic and dome-shaped with sharp protrusions on the convex surface to help shape the eyes and keep them closed. Similarly, mouth formers are used to help shape the mouth. They are usually applied when there are no teeth to shape the lips.
Sources: en.wikipedia.org
Two alpha subunits and two beta subunits make up the IGF-1 receptor. Both the α and β subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane αβ chain. The α chains are located extracellularly, while the β subunit spans the membrane and is responsible for intracellular signal transduction upon ligand stimulation. The mature IGF-1R has a molecular weight of approximately 320 kDa.citation? The receptor is a member of a family which consists of the insulin receptor and the IGF-2R (and their respective ligands IGF-1 and IGF-2), along with several IGF-binding proteins. IGF-1R and the insulin receptor both have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF-1R and the insulin receptor. The structures of the autophosphorylation complexes of tyrosine residues 1165 and 1166 have been identified within crystals of the IGF1R kinase domain. In response to ligand binding, the α chains induce the tyrosine autophosphorylation of the β chains. This event triggers a cascade of intracellular signaling that, while cell type-specific, often promotes cell survival and cell proliferation.
from its lipids. By comparison with synthetically produced fatty acids, they were able to determine the position of the cyclopropane ring and proposed the name 11,12-methyleneoctadecanoic acid, without specifying the stereoisomerism of the structure. Viewed from the cyclopropane ring, different substituents are present on two carbon atoms, resulting in cis-trans-isomerism (see figure). The substituents can be on the same side (cis) or on different sides (trans) of the ring bond. Hofmann et al. were initially unable to clarify which structure was actually present at the time of discovery. However, in 1954 they hypothesized that the cis isomer was present. This was confirmed by a Canadian research group in 2005. A clear description of the spatial arrangement of the substituents is possible with the help of the Cahn-Ingold-Prelog priority rules, according to which the absolute configuration of the molecule is given as 11R,12S. The derived name (11R,12S)-methylenoctadecanoic acid is commonly used, even if it does not correspond to the recommendations of the IUPAC nomenclature. For the systematic naming of lactobacillic acid, the absolute configuration is given from the cyclopropane ring, with a C6 substituent (hexyl group) and a C10 substituent containing the carboxy group (decanoic acid), thus giving 10-[(1R,2S)-2-hexylcyclopropyl]decanoic acid
The main result that is measured at the end of a study to see if a given treatment worked (e.g., the number of deaths or the difference in survival between the treatment group and the control group). What the primary endpoint will be is decided before the study begins. (NCI) Prospective
=== Jim Dycker === James "Jim" Dycker (Charlie Heaton) is an intrepid financial journalist at FinDigest who is investigating Tender. A former trader who suffered major losses in the collapse of FTX, Jim is now determined to revive his career by being the one to break the story on Tender's misconduct. He shares custody of an infant son with his colleague Elaine, who he impregnated during a one-night stand. At the start of series 4, Jim follows Tender executive assistant Hayley Clay to a club, and the two spend the night in her apartment while she is intoxicated; she is enraged when he reveals his identity to her the following morning. Before Hayley kicks him out, Jim encourages her to look into the mysterious circumstances surrounding her predecessor's exit from the company. Jim later gets in touch with Harper, who is running a short-only fund, and tips her off that Tender is a strong target, having discovered that they are continuing to illegally process porn and gambling payments out of Africa despite publicly distancing themselves from those sectors to pivot to banking. Jim's tip leads Harper on her own investigation, but Jim himself is forced to publish a heavily edited version of the story. Tender leadership conspires to silence Jim after his discoveries, with Yasmin enlisting Lord Norton to defame Jim in the press as colluding with short sellers, using photos of him meeting Harper. Furthermore, Hayley files a sexual assault complaint against Jim.
Side effects have been mostly mild to moderate and manageable, with no significant liver, eye, or kidney toxicity reported. The ATAC approach is also showing potential in solid tumors. TROP2-targeted conjugates have completely eradicated tumors in preclinical models of pancreatic cancer and triple-negative breast cancer, outperforming the approved drug sacituzumab govitecan. In January 2026, Takeda began a Phase I/II clinical trial of an ATAC candidate for solid tumors. These advances have been reviewed in a 2026 editorial by Italian amanitologist Danny LeVan-Cicchetti, demonstrating how α-amanitin can overcome drug resistance and attack the hidden roots of cancer, offering new promising hope in precision oncology as of May 2026.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.